These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12499171)

  • 1. Susceptibility of Candida dubliniensis to salivary histatin 3.
    Fitzgerald DH; Coleman DC; O'Connell BC
    Antimicrob Agents Chemother; 2003 Jan; 47(1):70-6. PubMed ID: 12499171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole.
    Martinez M; López-Ribot JL; Kirkpatrick WR; Coco BJ; Bachmann SP; Patterson TF
    J Clin Microbiol; 2002 Sep; 40(9):3135-9. PubMed ID: 12202543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients.
    Chavanet P; Lopez J; Grappin M; Bonnin A; Duong M; Waldner A; Buisson M; Camerlynck P; Portier H
    AIDS; 1994 Jul; 8(7):945-50. PubMed ID: 7946104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iranian HIV/AIDS patients with oropharyngeal candidiasis: identification, prevalence and antifungal susceptibility of Candida species.
    Khedri S; Santos ALS; Roudbary M; Hadighi R; Falahati M; Farahyar S; Khoshmirsafa M; Kalantari S
    Lett Appl Microbiol; 2018 Oct; 67(4):392-399. PubMed ID: 30019443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.
    Kirkpatrick WR; Revankar SG; Mcatee RK; Lopez-Ribot JL; Fothergill AW; McCarthy DI; Sanche SE; Cantu RA; Rinaldi MG; Patterson TF
    J Clin Microbiol; 1998 Oct; 36(10):3007-12. PubMed ID: 9738058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection.
    Tumbarello M; Caldarola G; Tacconelli E; Morace G; Posteraro B; Cauda R; Ortona L
    J Antimicrob Chemother; 1996 Oct; 38(4):691-9. PubMed ID: 8937963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro.
    Moran GP; Sullivan DJ; Henman MC; McCreary CE; Harrington BJ; Shanley DB; Coleman DC
    Antimicrob Agents Chemother; 1997 Mar; 41(3):617-23. PubMed ID: 9056003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis: cross resistance to itraconazole and ketoconazole].
    Metzger S; Hofmann H
    Mycoses; 1997; 40 Suppl 1():56-63. PubMed ID: 9417515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.
    Perea S; López-Ribot JL; Wickes BL; Kirkpatrick WR; Dib OP; Bachmann SP; Keller SM; Martinez M; Patterson TF
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1695-703. PubMed ID: 12019078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species distribution and antifungal susceptibility profile of oral candida isolates from HIV-infected patients in the antiretroviral therapy era.
    Costa CR; de Lemos JA; Passos XS; de Araújo CR; Cohen AJ; Souza LK; Silva Mdo R
    Mycopathologia; 2006 Jul; 162(1):45-50. PubMed ID: 16830191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
    Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
    Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
    Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
    J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence of different Candida dubliniensis isolates in the presence of fluconazole.
    Borg-von Zepelin M; Niederhaus T; Gross U; Seibold M; Monod M; Tintelnot K
    AIDS; 2002 Jun; 16(9):1237-44. PubMed ID: 12045488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression.
    Pinjon E; Jackson CJ; Kelly SL; Sanglard D; Moran G; Coleman DC; Sullivan DJ
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1312-8. PubMed ID: 15793103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluconazole-Resistant Candida auris Is Susceptible to Salivary Histatin 5 Killing and to Intrinsic Host Defenses.
    Pathirana RU; Friedman J; Norris HL; Salvatori O; McCall AD; Kay J; Edgerton M
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158282
    [No Abstract]   [Full Text] [Related]  

  • 17. Susceptibility of Candida albicans isolates from the oral cavities of HIV-positive patients to histatin-5.
    Nikawa H; Jin C; Makihira S; Hamada T; Samaranayake LP
    J Prosthet Dent; 2002 Sep; 88(3):263-7. PubMed ID: 12426495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in antifungal susceptibility of clones of Candida albicans isolated on single and sequential visits from a HIV-infected southern Chinese cohort.
    Samaranayake YH; Samaranayake LP; Tsang PC; Wong KH; Yeung KW
    J Oral Pathol Med; 2001 Jul; 30(6):336-46. PubMed ID: 11459319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of Candida biofilms to histatin 5 and fluconazole.
    Konopka K; Dorocka-Bobkowska B; Gebremedhin S; Düzgüneş N
    Antonie Van Leeuwenhoek; 2010 May; 97(4):413-7. PubMed ID: 20140514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of fluconazole and itraconazole in the treatment of oral candidiasis in HIV patients.
    Menon T; Umamaheswari K; Kumarasamy N; Solomon S; Thyagarajan SP
    Acta Trop; 2001 Oct; 80(2):151-4. PubMed ID: 11600094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.